Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis-associated inflammatory bowel disease (PSC-IBD): A matched analysis from the Paediatric PSC Consortium

Ricciuto, A., Liu, K., El‐Matary, W., Amin, M., Amir, A. Z., Aumar, M., Auth, M., Di Guglielmo, M. D., Druve Tavares Fagundes, E., Rodrigues Ferreira, A., Furuya, K. N., Gupta, N., Guthery, S., Horslen, S. P., Jensen, K., Kamath, B. M., Kerkar, N., Koot, B. G. P., … Laborda, T. J. (2024). Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis‐associated inflammatory bowel disease (PSC‐IBD): A matched analysis from the Paediatric PSC Consortium. Alimentary Pharmacology & Therapeutics, 59(10), 1236–1247. Portico. https://doi.org/10.1111/apt.17936
Authors:
Amanda Ricciuto
Kuan Liu
Wael El-Matary
Mansi Amin
Achiya Z Amir
Madeleine Aumar
Marcus Auth
Matthew D Di Guglielmo
Eleonora Druve Tavares Fagundes
Alexandre Rodrigues Ferreira
Katryn N Furuya
Nitika Gupta
Stephen Guthery
Simon P Horslen
Kyle Jensen
Binita M Kamath
Nanda Kerkar
B G P Koot
Trevor J Laborda
Christine K Lee
Kathleen M Loomes
Cara Mack
Mercedes Martinez
Aldo Montano-Loza
Nadia Ovchinsky
Alexandra Papadopoulou
Emily R Perito
Pushpa Sathya
Kathleen B Schwarz
Uzma Shah
Eyal Shteyer
Nisreen Soufi
James Patrick Stevens
Amy Taylor
M Elizabeth Tessier
Pamela Valentino
Marek Woynarowski
Mark Deneau
Affiliated Authors:
Mercedes Martinez
Columbia Affiliation:
Subjects:
Vancomycin (MeSH)
Cholangitis, Sclerosing (MeSH)
Anti-Bacterial Agents (MeSH)
Inflammatory Bowel Diseases (MeSH)
elink
Publication Type:
Article
Unique ID:
10.1111/apt.17936
PMID:
38462727
DOI:
10.1111/apt.17936
Journal:
Alimentary Pharmacology and Therapeutics
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record
View Scopus Record
View Web of Science Record

Record Created: